Nasdaq · Biotech stocks database
SNY (Sanofi) stock: $47.04, $114.72B market cap, $8.62B cash, $127.15B EV, $113.28B fully diluted market cap. Lead program: Dupilumab (Eosinophilic Oesophagitis), Phase 4. Data from Fully Diluted's biotech stocks database.
Sanofi’s activities are organized around the following categories within the Biopharma operating segment: Immunology, Rare Diseases, Neurology, Oncology, Other Medicines and Vaccines. The company describes itself as an AI-powered biopharma committed to improving people’s lives through R&D innovation and manufacturing.
Source: 20-F FY2025 via SEC EDGAR
| Cash | $8,616.4M |
|---|---|
| Debt | $21,045.4M |
| Net cash | -$12,429.0M |
| Enterprise value | $127,152.7M |
| Basic shares | 2,408.1M shares |
| Fully diluted shares | 2,408.1M shares |
| Fully diluted market cap | $113,278.4M |
| Cash per share | $3.58 |
Cash figures as of 2025-12-31. Database snapshot: 2026-11-07.
Cap table as of 2025-12-31.
Loading SNY daily closes…
Rilzabrutinib dose 1 · Now - Nov 17, 2026 Now · Phase 2 · Graves' Disease
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|---|---|---|---|
| Now - Nov 17, 2026 Now | Rilzabrutinib dose 1 | Phase 2 | Graves' Disease | — |
| Now - Nov 26, 2026 Now | SAR441344 IV | Phase 2 | Systemic Lupus Erythematosus | — |
| GUIDEDEst. Nov 15, 2026 Now guidance midpoint | Sarclisa (isatuximab) Phase 3 in transplant-eligible multiple myeloma | Phase 3 | transplant-eligible multiple myeloma | remainder of 2026 |
| GUIDEDNov 25, 2026 in 18d | venglustat LEAP2MONO Phase 3 in type 3 Gaucher disease (FDA NDA under priority review) · NCT05222906 | Phase 3 | type 3 Gaucher disease (FDA NDA under priority review) | November 25, 2026 |
| Nov 9 - Dec 21 in 2d | Belumosudil | Phase 1 | Chronic Graft Versus Host Disease | — |
| Nov 10 - Dec 22 in 3d | Amlitelimab | Phase 2 | Asthma | — |
| Nov 11 - Dec 23 in 4d | balinatunfib | Phase 2 | Colitis Ulcerative; Crohn's Disease | — |
| Nov 11 - Dec 23 in 4d | Dupilumab coformulated with berahyaluronidase alfa | Phase 1 | Healthy Volunteers | — |
| Nov 18 - Dec 30 in 11d | Dupilumab | Phase 3 | Atopic Dermatitis | — |
| Nov 25, 2026 - Jan 6, 2027 in 18d | Itepekimab (SAR440340) | Phase 3 | Chronic Rhinosinusitis With Nasal Polyps | — |
| Dec 11, 2026 - Jan 22, 2027 in 5 wks | venglustat (GZ402671) | Phase 2 | Gaucher Disease Type 1; Gaucher Disease Type 3 | — |
| Dec 13, 2026 - Jan 24, 2027 in 5 wks | Amlitelimab | Phase 2 | Interstitial Lung Disease Due to Systemic Disease; Scleroderma | — |
| Dec 17, 2026 - Jan 28, 2027 in 6 wks | Fitusiran | Phase 3 | Hemophilia | — |
| Dec 18, 2026 - Jan 29, 2027 in 6 wks | Itepekimab (SAR440340) | Phase 3 | Chronic Rhinosinusitis With Nasal Polyps | — |
| Jan 11 - Feb 22 in 9 wks | rilzabrutinib | Phase 3 | Immune Thrombocytopenia | — |
| Jan 12 - Feb 23 in 9 wks | Itepekimab (SAR440340) | Phase 3 | Chronic Obstructive Pulmonary Disease | — |
| Jan 12 - Feb 23 in 9 wks | PCV21 | Phase 3 | Pneumococcal Infections | 2027 Est. Jan 12, 2027 · PCD + 6 wks (Jan 1-Jan 26) |
| Jan 28 - Mar 11 in 12 wks | SAR442970 | Phase 2 | Crohn's Disease | — |
| Jan 28 - Mar 11 in 12 wks | SAR442970 | Phase 2 | Ulcerative Colitis | — |
| Feb 3 - Mar 17 in 13 wks | frexalimab | Phase 2 | Focal Segmental Glomerulosclerosis; Glomerulonephritis Minimal Lesion | — |
| Feb 11 - Mar 25 in 14 wks | Belumosudil | Phase 2 | Chronic Graft Versus Host Disease | — |
| Feb 18 - Apr 1 in 15 wks | PCV21 | Phase 3 | Sickle Cell Disease | 2027 Est. Feb 18, 2027 · PCD + 6 wks (Feb 4-Mar 4) |
| Feb 19 - Apr 2 in 15 wks | Isatuximab SC-OBDS | Phase 2 | Plasma Cell Myeloma Refractory | — |
| Feb 26 - Apr 9 in 16 wks | efanesoctocog alfa (BIVV001) | Phase 3 | Hemophilia A | — |
| Mar 2 - Apr 13 in 16 wks | SAR445877 | Phase 2 | Solid Tumor | — |
| Mar 23 - May 4 in 5 mo | Brivekimig | Phase 2 | Hidradenitis Suppurativa | 2027 Est. Mar 23, 2027 · PCD + 6 wks (Mar 9-Apr 6) |
| Mar 31 - May 12 in 5 mo | Itepekimab (SAR440340) | Phase 3 | Chronic Rhinosinusitis With Nasal Polyps | — |
| May 6 - Jun 17 in 6 mo | Fitusiran | Phase 3 | Hemophilia | — |
| May 16 - Jun 27 in 6 mo | H5 Flu Investigational Medical Product (IMP) 1 | Phase 1 | Respiratory Syncytial Virus (RSV); Influenza A(H5N1) | — |
| May 17 - Jun 28 in 6 mo | Isatuximab SAR650984 | Phase 3 | Plasma Cell Myeloma | — |
| May 20 - Jul 1 in 6 mo | SAR444336 | Phase 2 | Microscopic Colitis | — |
| Jun 9 - Jul 21 in 7 mo | Frexalimab | Phase 2 | Type 1 Diabetes Mellitus | — |
| Jun 10 - Jul 22 in 7 mo | Brivekimig | Phase 2 | Type 1 Diabetes Mellitus | — |
| GUIDEDEst. Jul 2, 2027 in 8 wks guidance midpoint | riliprubart Phase 3 in CIDP (vs IVIG) | Phase 3 | CIDP (vs IVIG) | 2027 |
| GUIDEDEst. Jul 2, 2027 in 8 wks guidance midpoint | yellow fever vaccine Phase 3 yellow fever vaccine | Phase 3 | Not disclosed | 2027 |
| Jun 17 - Jul 29 in 7 mo | Frexalimab | Phase 3 | Multiple Sclerosis | 2027 Est. Jun 17, 2027 · PCD + 6 wks (Jun 3-Jul 1) |
| Jun 29 - Aug 10 in 8 mo | SAR402663 | Phase 2 | Neovascular Age-related Macular Degeneration | — |
| Jul 14 - Aug 25 in 8 mo | Dupilumab | Phase 3 | Pruritus | — |
| Aug 2 - Sep 13 in 9 mo | Lunsekimig | Phase 2 | Asthma | — |
| Aug 20 - Oct 1 in 10 mo | riliprubart | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy | — |
| Aug 26 - Oct 7 in 10 mo | Frexalimab | Phase 3 | Multiple Sclerosis | 2027 Est. Aug 26, 2027 · PCD + 6 wks (Aug 12-Sep 9) |
| Sep 3 - Oct 15 in 10 mo | Rilzabrutinib | Phase 3 | Sickle Cell Disease | — |
| Oct 25 - Dec 6 in 12 mo | Isatuximab | Phase 2 | Plasma Cell Myeloma Refractory | — |
| Nov 3 - Dec 15 in 12 mo | SAR445399 | Phase 2 | Hidradenitis Suppurativa | — |
| Nov 11 - Dec 23 in 12 mo | Amlitelimab | Phase 3 | Dermatitis Atopic | — |
| Nov 24, 2027 - Jan 5, 2028 in 13 mo | SAR446597 | Phase 2 | Geographic Atrophy | — |
| Dec 9, 2027 - Jan 20, 2028 in 13 mo | Dupilumab | Phase 3 | Prurigo Nodularis | — |
| Dec 17, 2027 - Jan 28, 2028 in 14 mo | rilzabrutinib | Phase 3 | Immune Thrombocytopenia | — |
| Jan 12 - Feb 23 in 14 mo | Lenalidomide | Phase 2 | Newly Diagnosed Multiple Myeloma | — |
| Mar 3 - Apr 14 in 16 mo | SAR448501 | Phase 1 | B-cell Non Hodgkin Lymphoma | — |
| Mar 29 - May 10 in 17 mo | SAR447971 | Phase 1 | Hidradenitis; Healthy Volunteers | — |
| Apr 12 - May 24 in 17 mo | Sarilumab SAR153191 (REGN88) | Phase 2 | Juvenile Idiopathic Arthritis | — |
| Apr 17 - May 29 in 18 mo | Teplizumab | Phase 2 | Type 1 Diabetes Mellitus | — |
| May 5 - Jun 16 in 18 mo | Frexalimab | Phase 3 | Multiple Sclerosis | 2027 Est. Dec 31, 2027 · PCD + 6 wks (Dec 31-Dec 31) |
| Jun 14 - Jul 26 in 20 mo | RSV | Phase 2 | Respiratory Syncytial Virus Immunization; Human Metapneumovirus Immunization; Healthy Volunteers | — |
| Jun 20 - Aug 1 in 20 mo | Duvakitug | Phase 3 | Ulcerative Colitis | — |
| Jul 12 - Aug 23 in 20 mo | rilzabrutinib | Phase 3 | Autoimmune Haemolytic Anaemia | — |
| Jul 18 - Aug 29 in 21 mo | Teplizumab | Phase 3 | Type 1 Diabetes Mellitus | — |
| Jul 28 - Sep 8 in 21 mo | Duvakitug | Phase 2 | Hidradenitis | — |
| Jul 31 - Sep 11 in 21 mo | dupilumab | Phase 3 | Eosinophilic Esophagitis (EoE) | — |
| Aug 9 - Sep 20 in 21 mo | Rilzabrutinib | Phase 3 | Immunoglobulin G4 Related Disease | — |
| Aug 11 - Sep 22 in 21 mo | SAR447537 | Phase 2 | Alpha 1-Antitrypsin Deficiency; Emphysema | — |
| Aug 14 - Sep 25 in 22 mo | Bivalent RSV | Phase 2 | Respiratory Syncytial Virus; Human Metapneumovirus; Healthy Volunteers | — |
| Sep 13 - Oct 25 in 23 mo | SAR445877 | Phase 2 | Gastric Cancer; Oesophageal Carcinoma | — |
| Nov 2 - Dec 14 in 24 mo | Duvakitug | Phase 3 | Ulcerative Colitis | — |
| Nov 6 - Dec 18 in 24 mo | Belumosudil | Phase 2 | Chronic Graft Versus Host Disease | — |
| Nov 10 - Dec 22 in 24 mo | Belumosudil | Phase 3 | Chronic Graft Versus Host Disease | — |
| Dec 7, 2028 - Jan 18, 2029 in 25 mo | Sarilumab, SAR153191 SC | Phase 2 | Rheumatoid Arthritis | — |
| Jan 11 - Feb 22 in 27 mo | Isatuximab intravenous (IV) | Phase 2 | Plasma Cell Myeloma | — |
| Feb 1 - Mar 15 in 27 mo | Dupilumab | Phase 3 | Wheezing; Asthma | — |
| Mar 5 - Apr 16 in 28 mo | Amlitelimab | Phase 3 | Dermatitis Atopic | — |
| Mar 12 - Apr 23 in 29 mo | Belumosudil | Phase 3 | Lung Transplant Rejection | — |
| Apr 11 - May 23 in 30 mo | SAR446268 | Phase 2 | Myotonic Dystrophy | — |
| Jun 11 - Jul 23 in 32 mo | Tolebrutinib | Phase 3 | Relapsing Multiple Sclerosis; Secondary Progressive Multiple Sclerosis; Progressive Relapsing Multiple Sclerosis | — |
| Jun 25 - Aug 6 in 32 mo | Duvakitug | Phase 3 | Crohn's Disease | — |
| Aug 6 - Sep 17 in 33 mo | SAR448501 | Phase 1 | Systemic Lupus Erythematosus (SLE); Rheumatoid Arthritis (RA) | — |
| Sep 11 - Oct 23 in 35 mo | SAR448851 | Phase 2 | Dementia, Alzheimer's Type; Alzheimer's Disease | — |
| Sep 15 - Oct 27 in 35 mo | Fitusiran | Phase 3 | Hemophilia | — |
| Sep 24 - Nov 5 in 35 mo | Duvakitug | Phase 3 | Crohn's Disease | — |
| Sep 26 - Nov 7 in 35 mo | Frexalimab | Phase 3 | Kidney Transplant Rejection | — |
| Oct 13 - Nov 24 in 36 mo | BLU-924 | Phase 2 | Advanced Solid Tumor; Non-Small Cell Lung Cancer; Colorectal Neoplasms | — |
| Oct 24 - Dec 5 in 36 mo | PF-08046050 | Phase 1 | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Stomach Neoplasms | — |
| Oct 26 - Dec 7 in 36 mo | Belumosudil | Phase 3 | Chronic Graft Versus Host Disease | — |
| Nov 14 - Dec 26 in 37 mo | Riliprubart Prefilled Pen (PFP) | Phase 3 | Polyneuropathy, Inflammatory Demyelinating, Chronic | — |
| Jan 8 - Feb 19 in 39 mo | Lunsekimig | Phase 3 | Chronic Obstructive Pulmonary Disease | — |
| Jan 8 - Feb 19 in 39 mo | Lunsekimig | Phase 3 | Chronic Obstructive Pulmonary Disease | — |
| May 14 - Jun 25 in 43 mo | SAR444836 | Phase 2 | Phenylketonuria | — |
| Nov 25, 2030 - Jan 6, 2031 in 49 mo | Isatuximab SAR650984 | Phase 3 | Plasma Cell Myeloma | — |
| Mar 3 - Apr 14 in 53 mo | Lunsekimig | Phase 2 | Asthma | — |
| Mar 12 - Apr 23 in 53 mo | Lunsekimig | Phase 2 | Chronic Rhinosinusitis With Nasal Polyps | — |
| Jun 27 - Aug 8 in 56 mo | SAR446523 | Phase 1 | Plasma Cell Myeloma Refractory | — |
| Jul 23 - Sep 3 in 57 mo | Amlitelimab | Phase 2 | Dermatitis Atopic | — |
| Jul 25 - Sep 5 in 57 mo | Blood draw for the laboratory assessment | Phase 2 | Usher's Syndrome | — |
| Sep 3 - Oct 15 in 59 mo | Lunsekimig | Phase 3 | Chronic Obstructive Pulmonary Disease | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Per-asset detail extracted from the 20-F filed 2026-02-17. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
| Lead drug | Dupilumab |
|---|---|
| Lead indication | Eosinophilic Oesophagitis |
| Lead phase | Phase 4 |
| Active trials | 181 |
| Collaborator trials | 118 |
| Trial | Phase | Status | Role | Sponsor | BP | Condition(s) | Mgmt guide |
|---|---|---|---|---|---|---|---|
| NCT06834347 | Phase 3 | Active, not recruiting | Sponsor | SNY | REGN | Chronic Rhinosinusitis With Nasal Polyps | — |
| NCT03754790 | Phase 3 | Active, not recruiting | Sponsor | SNY | — | Hemophilia | — |
| NCT06834360 | Phase 3 | Active, not recruiting | Sponsor | SNY | REGN | Chronic Rhinosinusitis With Nasal Polyps | — |
| NCT07216079 | Phase 3 | Active, not recruiting | Sponsor | SNY | — | Immune Thrombocytopenia | — |
| NCT06208306 | Phase 3 | Active, not recruiting | Sponsor | SNY | REGN | Chronic Obstructive Pulmonary Disease | — |
| NCT06838000 | Phase 3 | Active, not recruiting | Sponsor | SNY | — | Pneumococcal Infections | 2027 Est. Jan 12, 2027 · PCD + 6 wks (Jan 1-Jan 26) |
| NCT07247188 | Phase 3 | Recruiting | Sponsor | SNY | — | Sickle Cell Disease | 2027 Est. Feb 18, 2027 · PCD + 6 wks (Feb 4-Mar 4) |
| NCT04644575 | Phase 3 | Active, not recruiting | Sponsor | SNY | — | Hemophilia A | — |
| NCT07424144 | Phase 3 | Active, not recruiting | Sponsor | SNY | REGN | Chronic Rhinosinusitis With Nasal Polyps | — |
| NCT05662319 | Phase 3 | Active, not recruiting | Sponsor | SNY | — | Hemophilia | — |
| NCT03319667 | Phase 3 | Active, not recruiting | Sponsor | SNY | — | Plasma Cell Myeloma | remainder of 2026 Est. Dec 31, 2026 · PCD + 6 wks (Dec 31-Dec 31) |
| NCT06141473 | Phase 3 | Active, not recruiting | Sponsor | SNY | — | Multiple Sclerosis | 2027 Est. Jun 17, 2027 · PCD + 6 wks (Jun 3-Jul 1) |
Sponsor-matched active trials from ClinicalTrials.gov (181 as sponsor, 118 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
| Fund | Shares | Q/Q change | % of portfolio | Filing |
|---|---|---|---|---|
| Sphera Biotech | 269,515 | no change | 1.65% | 2026-08-14 |
| ADAR1 Capital Management | 57,100 | -259,839 | 0.11% | 2026-08-14 |
Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.